Clinical trial
Docetaxel Alone or in Combination With Vaccine to Treat Breast Cancer
NCT00179309 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00179309 |
|---|---|
| Title | Docetaxel Alone or in Combination With Vaccine to Treat Breast Cancer |
| Official title | A Randomized Pilot Phase II Study of Docetaxel Alone or in Combination With PANVAC(Trademark)-V (Vaccinia) and PANVAC(Trademark)-F (Fowlpox) in Adults With Metastatic Breast Cancer |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Biological, Drug |
| Interventions | Docetaxel, PANVAC-V, PANVAC-F, Sargramostim |
| Enrollment | 48 |
| Start date | Sep 1, 2005 |
| Primary completion | Feb 1, 2013 |
| Completion | Oct 1, 2013 |
| First posted | Sep 15, 2005 |
| Last update posted | Jul 15, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: